BR112014007603A2 - métodos de tratamento do câncer - Google Patents

métodos de tratamento do câncer

Info

Publication number
BR112014007603A2
BR112014007603A2 BR112014007603A BR112014007603A BR112014007603A2 BR 112014007603 A2 BR112014007603 A2 BR 112014007603A2 BR 112014007603 A BR112014007603 A BR 112014007603A BR 112014007603 A BR112014007603 A BR 112014007603A BR 112014007603 A2 BR112014007603 A2 BR 112014007603A2
Authority
BR
Brazil
Prior art keywords
cancer treatment
treatment methods
cancer
methods
treatment
Prior art date
Application number
BR112014007603A
Other languages
English (en)
Inventor
L Creasy Caretha
Ganji Gopinath
N Smitheman Kimberly
T Mccabe Michael
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of BR112014007603A2 publication Critical patent/BR112014007603A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91005—Transferases (2.) transferring one-carbon groups (2.1)
    • G01N2333/91011—Methyltransferases (general) (2.1.1.)
    • G01N2333/91017—Methyltransferases (general) (2.1.1.) with definite EC number (2.1.1.-)
BR112014007603A 2011-09-30 2012-09-30 métodos de tratamento do câncer BR112014007603A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161541304P 2011-09-30 2011-09-30
PCT/US2012/058188 WO2013049770A2 (en) 2011-09-30 2012-09-30 Methods of treating cancer

Publications (1)

Publication Number Publication Date
BR112014007603A2 true BR112014007603A2 (pt) 2017-06-13

Family

ID=47996781

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014007603A BR112014007603A2 (pt) 2011-09-30 2012-09-30 métodos de tratamento do câncer

Country Status (10)

Country Link
US (2) US9730925B2 (pt)
EP (1) EP2760452A4 (pt)
JP (1) JP2014534178A (pt)
KR (1) KR20140082742A (pt)
CN (1) CN103987842A (pt)
AU (1) AU2012315566A1 (pt)
BR (1) BR112014007603A2 (pt)
CA (1) CA2850570A1 (pt)
RU (1) RU2014117632A (pt)
WO (1) WO2013049770A2 (pt)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2841142C (en) 2010-06-23 2020-12-15 Ryan D. Morin Biomarkers for non-hodgkin lymphomas and uses thereof
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
RU2618475C2 (ru) 2010-09-10 2017-05-03 Эпизайм, Инк. Ингибиторы ezh2 человека и способы их применения
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
US9051269B2 (en) 2011-11-18 2015-06-09 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
CA2862289C (en) 2012-02-10 2019-11-26 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
ES2718900T3 (es) * 2012-03-12 2019-07-05 Epizyme Inc Inhibidores de EZH2 humana y métodos de uso de los mismos
PE20150887A1 (es) 2012-10-15 2015-06-04 Epizyme Inc Compuestos de benceno sustituidos
NZ706836A (en) 2012-10-15 2019-02-22 Epizyme Inc Methods of treating cancer
EP2934531A4 (en) * 2012-12-19 2016-06-15 Glaxosmithkline Llc COMBINATION
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
CA2905070A1 (en) 2013-03-14 2014-09-25 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
EP2970305B1 (en) 2013-03-15 2017-02-22 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP2991980B1 (en) * 2013-04-30 2019-01-02 Glaxosmithkline Intellectual Property (No. 2) Limited Enhancer of zeste homolog 2 inhibitors
US20160194718A1 (en) * 2013-05-21 2016-07-07 Dana-Farber Cancer Institute, Inc. Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Cancer Using Histone H3K27ME3 Biomarkers and Modulators
US9556157B2 (en) 2013-07-10 2017-01-31 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
EP3033334A1 (en) 2013-08-15 2016-06-22 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
ES2705573T3 (es) * 2013-10-09 2019-03-26 Hoffmann La Roche Procedimientos y composiciones para detectar mutaciones en el gen EZH2 humano
US9822103B2 (en) 2013-11-22 2017-11-21 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
ES2863996T3 (es) 2013-12-06 2021-10-13 Epizyme Inc Terapia de combinación para el tratamiento del cáncer
WO2015132765A1 (en) * 2014-03-07 2015-09-11 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
WO2015143424A2 (en) * 2014-03-21 2015-09-24 Glaxosmithkline Intellectual Property (No. 2) Limited Methods of treating cancer
CN106999498B (zh) 2014-06-17 2021-06-08 Epizyme股份有限公司 用于治疗淋巴瘤的ezh2抑制剂
CR20160574A (es) 2014-06-17 2017-02-23 Pfizer Compuestos de dihidroisoquinolinona sustituida
WO2015193768A1 (en) * 2014-06-17 2015-12-23 Pfizer Inc. Aryl fused lactams as ezh2 modulators
MX2016017097A (es) * 2014-06-19 2017-05-01 Memorial Sloan Kettering Cancer Center Biomarcadores para la respuesta a inhibidores del mejorador del homologo 2 de zeste (ezh2).
RU2565548C1 (ru) * 2014-08-05 2015-10-20 Дмитрий Андреевич Журавлёв Способ получения плюрипотентных стволовых клеток
WO2016073956A1 (en) 2014-11-06 2016-05-12 Dana-Farber Cancer Institute, Inc. Ezh2 inhibitors and uses thereof
TW201636344A (zh) 2014-12-05 2016-10-16 美國禮來大藥廠 Ｅｚｈ２抑制劑
NZ731664A (en) 2014-12-23 2024-02-23 Novartis Ag Triazolopyrimidine compounds and uses thereof
US20180021331A1 (en) * 2014-12-30 2018-01-25 University Of Utah Research Foundation Hdac1,2 inhibitors and methods of using the same
EP3283502A4 (en) 2015-04-07 2019-04-03 The General Hospital Corporation METHODS FOR REACTIVATION OF GENES ON INACTIVE X CHROMOSOME
EP3285773A4 (en) 2015-04-20 2019-04-10 Epizyme, Inc. POLY THERAPY FOR THE TREATMENT OF CANCER
EP3307713A4 (en) * 2015-06-10 2019-01-23 Epizyme, Inc. EZH2 INHIBITOR FOR THE TREATMENT OF LYMPHOMA
WO2017035234A1 (en) 2015-08-24 2017-03-02 Epizyme, Inc. Method for treating cancer
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
WO2017040190A1 (en) 2015-08-28 2017-03-09 Constellation Pharmaceuticals, Inc. Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide
LT3378859T (lt) 2015-11-19 2020-01-27 Jiangsu Hengrui Medicine Co., Ltd. Benzofurano darinys, jo gavimo būdas ir jo panaudojimas medicinoje
US10633371B2 (en) 2016-04-22 2020-04-28 Dana-Farber Cancer Institute, Inc. EZH2 inhibitors and uses thereof
US10987353B2 (en) * 2016-05-04 2021-04-27 The Wistar Institute Of Anatomy And Biology Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and platinum-based antineoplastic drugs
CN109906224B (zh) 2016-06-20 2022-02-25 诺华股份有限公司 ***吡啶化合物及其应用
WO2017221100A1 (en) 2016-06-20 2017-12-28 Novartis Ag Imidazopyrimidine compounds useful for the treatment of cancer
US11091489B2 (en) 2016-06-20 2021-08-17 Novartis Ag Crystalline forms of a triazolopyrimidine compound
CN109790160B (zh) * 2016-09-07 2022-11-15 上海海和药物研究开发股份有限公司 吡啶并五元芳香环类化合物、其制备方法及用途
EP3529242A1 (en) 2016-10-19 2019-08-28 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of ezh2
AU2017351638A1 (en) 2016-10-26 2019-06-13 Genea Biocells USA (Holdings), Inc. Improved generation of muscle lineage cells and therapeutic uses thereof
KR101951289B1 (ko) * 2017-02-24 2019-02-22 사회복지법인 삼성생명공익재단 폐암 환자의 생존 예후 예측용 마커
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
CA3058496A1 (en) * 2017-05-18 2018-11-22 Jiangsu Hengrui Medicine Co., Ltd. Crystal of benzofuran derivative free base and preparation method
CN109937041B (zh) * 2017-05-18 2022-04-12 江苏恒瑞医药股份有限公司 一种ezh2抑制剂与btk抑制剂联合在制备***的药物中的用途
WO2018231973A1 (en) * 2017-06-13 2018-12-20 Epizyme, Inc. Inhibitors of ezh2 and methods of use thereof
US20210161883A1 (en) * 2017-07-10 2021-06-03 Constellation Pharmaceuticals, Inc. Ezh2 inhibitor-induced gene expression
US11529344B2 (en) 2017-11-14 2022-12-20 Pfizer Inc. EZH2 inhibitor combination therapies
DK3746446T3 (da) 2018-01-31 2022-06-27 Mirati Therapeutics Inc PRC2-inhibitorer
CN110229151B (zh) * 2018-03-06 2021-09-10 上海海和药物研究开发股份有限公司 吲嗪类化合物、其制备方法及用途
SG11202010006UA (en) 2018-04-09 2020-11-27 Ellevet Sciences Hemp extract for treatment of pain in animals
CA3111802A1 (en) * 2018-09-06 2020-03-12 The Council Of The Queensland Institute Of Medical Research Biomarkers for cancer therapy
US10800339B2 (en) 2018-10-16 2020-10-13 Ford Global Technologies, Llc Vehicle rack assembly and rack accessing method
WO2020123530A1 (en) * 2018-12-10 2020-06-18 The Regents Of The University Of California Compositions and methods for modulating transcriptional activity of amplified oncogenes contained on extrachromosomal dna
MX2021011118A (es) * 2019-03-15 2022-01-18 Fulcrum Therapeutics Inc Derivados de azolopiridina macrocíclicos como moduladores de eed y prc2.
WO2020219603A1 (en) 2019-04-22 2020-10-29 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Use of tg02 for treating gliomas in pediatric subjects
CN114727970A (zh) * 2019-07-02 2022-07-08 艾乐文特科学公司 用于治疗动物中的疼痛、癌症和癫痫的***提取物
WO2021035194A1 (en) 2019-08-22 2021-02-25 Juno Therapeutics, Inc. Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods
CN112782398A (zh) * 2020-12-28 2021-05-11 重庆生命知源科技有限公司 一种微量蛋白免疫印迹检测方法
WO2023025856A1 (en) 2021-08-25 2023-03-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of ezh2 inhibitors for the treatment of aortic valve stenosis
WO2023244917A1 (en) 2022-06-13 2023-12-21 Treeline Biosciences, Inc. 1,8-naphthyridin-2-one heterobifunctional bcl6 degraders
WO2023244918A1 (en) 2022-06-13 2023-12-21 Treeline Biosciences, Inc. Quinolone bcl6 bifunctional degraders
WO2023249714A1 (en) * 2022-06-24 2023-12-28 Memorial Sloan-Kettering Cancer Center Therapeutic compositions and methods for activating double stranded rna response in cancer patients via dnmt1 targeted therapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090012031A1 (en) 2007-07-03 2009-01-08 The Regents Of The University Of Michigan EZH2 Cancer Markers
WO2009015037A2 (en) * 2007-07-21 2009-01-29 Albany Molecular Research, Inc. 5-pyridinone substituted indazoles
US8846935B2 (en) * 2010-05-07 2014-09-30 Glaxosmithkline Llc Indazoles
BR112012028556A2 (pt) 2010-05-07 2014-04-01 Glaxosmithkline Llc Indóis
US9175331B2 (en) * 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
RU2618475C2 (ru) 2010-09-10 2017-05-03 Эпизайм, Инк. Ингибиторы ezh2 человека и способы их применения
JP5908493B2 (ja) 2010-12-01 2016-04-26 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ インドール
WO2012118812A2 (en) * 2011-02-28 2012-09-07 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس

Also Published As

Publication number Publication date
WO2013049770A2 (en) 2013-04-04
KR20140082742A (ko) 2014-07-02
US20140378470A1 (en) 2014-12-25
CN103987842A (zh) 2014-08-13
JP2014534178A (ja) 2014-12-18
CA2850570A1 (en) 2013-04-04
EP2760452A2 (en) 2014-08-06
AU2012315566A1 (en) 2014-04-17
RU2014117632A (ru) 2015-11-10
WO2013049770A3 (en) 2014-05-15
US9730925B2 (en) 2017-08-15
US20170348306A1 (en) 2017-12-07
EP2760452A4 (en) 2015-04-01

Similar Documents

Publication Publication Date Title
BR112014007603A2 (pt) métodos de tratamento do câncer
IL267242B (en) Cancer treatment
DK2707030T3 (da) Cancerbehandlinger
BR112014032105A2 (pt) método para o tratamento de câncer
BR112014002200A2 (pt) tratamento de câncer de mama
BR112014031806A2 (pt) método para tratamento de câncer positivo para gd2
BR112014012880A2 (pt) tratamento imunogênico do câncer
DK2785349T3 (da) Kombinationsbehandling af cancer
DK2717941T3 (da) Behandling af cancer
BR112013033974A2 (pt) terapia de combinação
BR112013011659A2 (pt) métodos de tratamento do câncer
DK2760886T3 (da) Immunocytokin-kombinationsterapi
FI20115876A0 (fi) Yhdistelmähoito
DK2489413T5 (da) Behandlingsapparat
BR112013022820A2 (pt) método de tratamento
BR112014011008A2 (pt) método de quantificação de tratamento de câncer
BR112013023142A2 (pt) método de tratamento de cabelos
BR112013022505A2 (pt) reconhecimento de campo de irradiação
CO6880064A2 (es) Métodos terapéuticos
HK1210023A1 (en) Cancer treatment
FI20115640A0 (fi) Yhdistelmähoito
CO6950447A2 (es) Aparato de tratamiento de espalda
CO6821930A2 (es) Métodos de tratamiento de biomasa
DK2694056T3 (da) Terapeutisk behandling
GB201222563D0 (en) Cancer treatment